WESTLAKE VILLAGE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), based on the results of the annual reconstitution of the index announced by Nasdaq on December 11, 2020. The inclusion will become effective prior to the U.S. market open on Monday, December 21, 2020.
News Ticker
- [ December 9, 2023 ] Quality Specialist II, Quality Assurance – Dendreon Corporation – Seal Beach, CA Los Angeles Biotech Jobs
- [ December 9, 2023 ] Product Release Coordinator- QA Pharmaceutical / Biotech – Full Time Days – Grifols – Los Angeles, CA Los Angeles Biotech Jobs
- [ December 8, 2023 ] “Frozen” Composer Christophe Beck and Kristen Bell Reunite at Education Through Music-Los Angeles Gala Los Angeles Biotech News
- [ December 8, 2023 ] Medical Lab Scientist – Techsara solutions Inc – Mission Viejo, CA Los Angeles Biotech Jobs
- [ December 8, 2023 ] City of Hope Doctors and Scientists Present Innovative Research at Largest Gathering on Breast Cancer Research Los Angeles Biotech News
Copyright © 2023 Biotech Networks, LLC
